Corvus Pharmaceuticals, Inc.
CRVS
Rank in Stocks
#8874
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Share Price
$11.35
Last synced: 2026-11-09
Market Cap
$954.77M
Change (1 day)
7.69%
Change (1 year)
38.75%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Corvus Pharmaceuticals, Inc. (CRVS)
Category
Healthcare
EPS for Corvus Pharmaceuticals, Inc. (CRVS)
EPS as of September 2026 TTM: $-0.74
According to Corvus Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-0.74. At the end of 2025 the company had an EPS of $-0.19, an increase over its 2024 EPS of $-1.02.
EPS history for Corvus Pharmaceuticals, Inc. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.74 | 289.47% |
| 2025 | $-0.19 | -81.37% |
| 2024 | $-1.02 | 81.24% |
| 2023 | $-0.56 | -36.76% |
| 2022 | $-0.89 | -13.59% |
| 2021 | $-1.03 | 415.00% |
| 2020 | $-0.20 | -86.58% |
| 2019 | $-1.49 | -12.87% |
| 2018 | $-1.71 | -37.13% |
| 2017 | $-2.72 | 15.25% |
| 2016 | $-2.36 | 53.25% |
| 2015 | $-1.54 | 49.51% |
| 2014 | $-1.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,216.22% |
US
|
|
| $-7.07 | 855.41% |
US
|
|
| $-5.29 | 614.86% |
AU
|
|
| $12.88 | -1,840.55% |
BE
|
|
| $21.56 | -3,013.51% |
NL
|
Questions about Corvus Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Corvus Pharmaceuticals, Inc.'s earnings per share (EPS)?
Corvus Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-0.74, as of Sep 2026.
What was Corvus Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Corvus Pharmaceuticals, Inc.'s earnings per share (EPS) was $-0.19, compared with $-1.02 in 2024.
How has Corvus Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Corvus Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.19) and lowest in 2021 ($-1.03).
How does Corvus Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Corvus Pharmaceuticals, Inc.'s earnings per share (EPS) ($-0.74) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.